Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy | MicrobiomeTrials← Back to trialsNCT07721025
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-25Est. Completion: 2032-06
Enrollment target: 26 participants Locations- University of South Florida, Tampa, Florida, United States
Other microbiome trials you might be interested in
Friedreich Ataxia
An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of C…
Los Angeles, United StatesEst. completion Jan 2027
Friedreich Ataxia
In this study, researchers will learn more about BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been …
Philadelphia, United StatesEst. completion Jun 4, 2030
Phase 2
Completed
In this study, researchers are learning more about RTA 408, also known as omaveloxolone, BIIB141, or SKYCLARYS®. The mai…
Los Angeles, United StatesCompleted Oct 31, 2019